Merck Shields $31.7B Keytruda Sales with 50 Patents, Enables $162K Infusion Prices
Merck’s Keytruda generated $31.7 billion in 2025, nearly half company revenue, while U.S. list prices start at $24,000 per dose and can reach $162,567.74 after middleman markups. The company holds over 50 active U.S. patents and more than 1,200 global applications to delay biosimilar competition and avoid Medicare price talks.
1. Pricing Dynamics and Middlemen
Merck lists Keytruda at $24,000 per standard dose in the U.S., but pharmacy benefit managers, insurers and health providers tack on rebates and fees that can push the cost of a single infusion to $162,567.74. These intermediaries capture roughly half of every dollar spent on brand medicines, driving up patient and payer expenses.
2. Revenue Impact
Keytruda accounted for $31.7 billion in worldwide sales in 2025, representing nearly 50% of Merck’s total revenue and about 60% of its U.S. sales. The drug’s blockbuster performance underpins much of Merck’s financial growth and investor expectations.
3. Patent Fortress Strategy
Merck holds over 50 active patents in the U.S. and has filed more than 1,200 applications across 53 countries, creating a patent thicket that could extend exclusivity until 2042. This strategy is aimed at deterring biosimilar makers from entering the market and preserving high price points.
4. Lobbying Against Medicare Negotiation
Merck has actively lobbied to prevent Medicare from negotiating Keytruda prices and has resisted proposals to adopt lower, weight-based dosing despite studies showing cost savings. The company maintains current dosing protocols to sustain revenue and pricing leverage.